Head and Neck Squamous Cell Carcinoma Clinical Trials

67 studies are recruiting for head and neck squamous cell carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality

   This clinical trial studies the use of virtual reality technology and three dimensional surgery (3D-surgery) modeling to enhance current treatments in head and neck cancer surgery. Virtual reality 3D-surgery modeling may improve quality of surgical planning and interdisciplinary communication betwe…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT05031910 on ClinicalTrials.gov

2. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

   Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   21 in total

   Run by

   Clasp Therapeutics, Inc.

   See if you can join NCT06778863 on ClinicalTrials.gov

3. Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

   This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cell…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Baylor St. Luke's Medical Center, Houston, Texas

   Run by

   Baylor College of Medicine

   See if you can join NCT03740256 on ClinicalTrials.gov

4. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

   A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dren Investigational Site, Denver, Colorado

   Locations

   10 in total

   Run by

   Dren Bio

   See if you can join NCT06999187 on ClinicalTrials.gov

5. Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

   This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately determine size and location of primary tumors compared to standard of care Fludeoxyglucose (18F-FDG) -PET/MRI in newly diagno…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   UAB, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT05183048 on ClinicalTrials.gov

6. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

   A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   St Vincent's Hospital, Darlinghurst, New South Wales

   Locations

   16 in total

   Run by

   OncoNano Medicine, Inc.

   See if you can join NCT06022029 on ClinicalTrials.gov

7. Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

   The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual (TAU) to improve the initiation of guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Washington University in St. Louis, St Louis, Missouri

   Locations

   4 in total

   Run by

   Medical University of South Carolina

   See if you can join NCT05793151 on ClinicalTrials.gov

8. Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

   Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have favorable outcomes and how well they do depends on the specific details about the patient and their cancer. How well they do isn't as related to the kinds of treatment they get. However, there are significant side …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Maryland Proton Treatment Center, Baltimore, Maryland

   Locations

   5 in total

   Run by

   University of Maryland, Baltimore

   See if you can join NCT06088381 on ClinicalTrials.gov

9. A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

   This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Southern California, Los Angeles, California

   Locations

   14 in total

   Run by

   Volastra Therapeutics, Inc.

   See if you can join NCT05902988 on ClinicalTrials.gov

10. A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

    The purpose of the study is to determine the activity and safety of ACR-368 (prexasertib) in combination with gemcitabine in participants with Head and Neck Squamous Cell Carcinoma (HNSCC). Participants will receive the study drugs ACR-368 and a low dose of gemcitabine once every 2 weeks in 4-week …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06597565 on ClinicalTrials.gov

11. Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

    This phase I trial evaluates the safety and effectiveness of using two imaging techniques, indium In 111 panitumumab (111In-panitumumab) with single photon emission computed tomography (SPECT)/computed tomography (CT) and panitumumab-IRDye800 fluorescence imaging during surgery (intraoperative), to…

    Stage

    Phase 1

    Ages

    19 and older

    Site

    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

    Run by

    Vanderbilt-Ingram Cancer Center

    See if you can join NCT05945875 on ClinicalTrials.gov

12. A Study of NX-1607 in Adults With Advanced Malignancies

    This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Southern California, Los Angeles, California

    Locations

    17 in total

    Run by

    Nurix Therapeutics, Inc.

    See if you can join NCT05107674 on ClinicalTrials.gov

13. A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

    This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in microdose quantities via the CIVO device.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    LSU Health Sciences Center, Shreveport, Louisiana

    Run by

    Pure Biologics S.A.

    See if you can join NCT06700070 on ClinicalTrials.gov

14. Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy

    This purpose of this study is to examine skin reactions (called radiation dermatitis) that occur during pencil beam scanning (PBS) proton therapy. The researchers will test a unique technique called "Spot Delete" to see if it can reduce skin reactions for head \& neck patients treated with PBS. The…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Thompson Proton Center, Knoxville, Tennessee

    Run by

    Covenant Health Cancer Center

    See if you can join NCT06183268 on ClinicalTrials.gov

15. Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

    This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    CHA University Bundang Medical Center, Seongnam,

    Locations

    11 in total

    Run by

    TiumBio Co., Ltd.

    See if you can join NCT05784688 on ClinicalTrials.gov

16. Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC

    This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck Squamous Cell Carcinoma. These are subjects who have undergone surgery or will be undergoing surgery.

    Stage

    Phase 2

    Ages

    18 to 79

    Site

    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT06693323 on ClinicalTrials.gov

17. Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

    This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

    Run by

    Vanderbilt-Ingram Cancer Center

    See if you can join NCT05996432 on ClinicalTrials.gov